组织纤溶酶原激活物 tissue plasminogen activator英语短句 例句大全

组织纤溶酶原激活物,tissue plasminogen activator

1)tissue plasminogen activator组织纤溶酶原激活物

1.METHOD Using aging rat models with blood stasis,the authors made observations on the effect of Liuwei Zihuang Decoction and its drug combination on rat in vitro thrombosis,serum lipid,brinase,tissue plasminogen activator(t-PA) and plasminogen activator inhibitor(PAI).方法本实验利用衰老加血瘀动物模型,观察了六味地黄汤及其配伍对模型大鼠体外血栓形成、血清脂质、纤维蛋白原(Fg)、组织纤溶酶原激活物(t-PA)和纤溶酶原激活抑制物(PAI)的影响。

2.Objective: To elucidate the effects of IL-6 on expression and secretion oftissue plasminogen activator (tPA) and plasminogen activator inhibitor type-1 (PAI-1) in human umbilical vein endothelial cells (HUVECs).目的:观察IL-6对脐静脉血管内皮细胞(HUVECs)表达组织纤溶酶原激活物(tPA)和纤溶酶原激活物抑制物1(PAI-1)的影响。

3.Tissue plasminogen activator antigen (t-PA), plasminogen activator inhi.对每例样本检测组织纤溶酶原激活物(t PA)抗原、组织纤溶酶原激活物抑制剂(PAI)、纤维蛋白(原)降解产物(FDP)和D 二聚体(D- D)。

英文短句/例句

1.The Studies of the Role of Tissue Plasminogen Activator in Brain Injury after Cerebral Ischemia;组织纤溶酶原激活物在脑缺血后神经损伤中的作用及其机制研究

2.The Initial Research about the Effect of Tissue Plasminogen Activator on Neural Repair组织纤溶酶原激活物对神经修复影响的初步探讨

3.Preliminary Study on DNA Family Shuffling of Tissue-type Plasminogen Activator Genes;组织型纤溶酶原激活物DNA改组的探索研究

4.Expressions of Survivin and uPA in human cerebral gliomas脑胶质瘤组织中Survivin和尿激酶型纤溶酶原激活物蛋白的表达

5.Intravenous thrombolytic therapy with recombinant-tissue plasminogen activator for super early stage of cerebral infarction重组组织型纤溶酶原激活物rt-PA静脉溶栓治疗超早期脑梗死

parison of Recombinant Tissue Plasminogen Activator, Urokinase and Defibrase in Vitro Simulation of Thrombolytic Test重组织型纤溶酶原激活剂、尿激酶和降纤酶体外溶栓效果比较

7.Relationship between the Changes of Activity of Tissue-Type Plasminogen Activator on Brains and Cerebral Edema in Asphyxia Status of Mice窒息鼠脑组织型纤溶酶原激活物活性变化与脑水肿的关系

8.The Climical Significance and Expression of Urinary Plasminogen Activator in Breast Cancer尿纤溶酶原激活物在乳腺良恶性组织中的表达及意义

9.DETERMINATION OF THE PLASMINOGEN ACTIVATOR IN THE TONSIL OF CHRONIC TONSILLITIS慢性扁桃体炎组织中的纤溶酶原激活剂测定

10.Clinical Study of the Expression of Tissue Factor and Urokinase Plasminogen Activator Receptor in Breast Cancer组织因子、尿激酶型纤溶酶原激活剂受体在乳腺癌中的表达

11.Evaluation of the therapeutic effect of thrombolytic therapy with rt-PA and nursing intervention in patients with acute myocardial infarction急性心肌梗死重组组织型纤溶酶原激活剂溶栓治疗的观察及护理

12.Therapeutic effect observation of thrombolysis with rt-PA intravenous in recurrent cerebral infarction重组组织型纤溶酶原激活剂对再发性脑梗死静脉溶栓治疗评价

13.Therapeutic Effect of Ultra Earlier Thrombolysis of Recombinant Tissue Plasminogen Activator in Acute Cerebral Infarction重组组织型纤溶酶原激活剂超早期溶栓治疗急性脑梗死的疗效

14.Thrombolytic therapy with intravenous recombinant tissue plasminogen activator for acute cerebral infarction重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死19例

15.The Effect of Astragalus and Safflower Mixture on Expression of Plasminogen Activator Inhibitor 1 in Renal Tubulointerstitial Fibrosis in Rats with Unilateral Ureteral Obstruction;芪红合剂对肾间质纤维化模型大鼠肾组织中纤溶酶原激活物抑制物-1表达的影响

16.Activity of plasma tissue plasminogen activator and plasminogen activator inhibitor in patients with hypertensive disorder complicating pregnancy妊娠期高血压疾病患者血浆组织型纤溶酶原激活物及其抑制物的活性变化

17.Experimental Study on Posterior Vitreous Detachment Induced by Tissue Plasminogen Activator Combined with Hyaluronidase in Rabbits;组织纤维蛋白溶酶原激活剂联合透明质酸酶致玻璃体后脱离的动物实验研究

18.The Recombinant Human Tissue-type Plasminogen Activator in the Treatment of Deep Venous Thrombosis of the Lower Extremities重组组织型纤溶酶原激活剂治疗下肢深静脉血栓形成的临床应用

相关短句/例句

tissue-type plasminogen activator组织纤溶酶原激活物

1.[Objective] The study was to investigate the effect of shear stress ontissue-type plasminogen activator (t-PA) mRNA expression in human endothelial progenitor cells (EPCs) and transplantation patency of endothelial progenitor cells (EPCs)-lined small diameter polyurethane artificial vessels.【目的】研究切应力对内皮祖细胞组织纤溶酶原激活物(tissue-type plasminogen activator,t-PA)基因表达和种植内皮祖细胞小径聚氨酯人工血管移植通畅率的影响。

2.In order to clonetissue-type plasminogen activator(tPA)gene,to construct the eukaryotic expres- sion plasmid pcDNA3.构建携带组织纤溶酶原激活物(tPA)基因真核表达质粒 pcDNA3。

3.Objective To detect the plasma plasminogen activator inhibitor 1(PAI-1),tissue-type plasminogen activator(t-PA) and urokinase-type plasminogen activator(uPA) levels in PCOS and explore the correlation between them and insulin resistance,obesity.目的观察多囊卵巢综合征(PCOS)患者外周血纤溶酶原激活抑制物1(PAI-1)、组织纤溶酶原激活物(t-PA)和尿激酶型纤溶酶原激活物(uPA)的水平,探讨其与肥胖及胰岛素抵抗的相关性。

3)Tissue-plasminogen activator组织纤溶酶原激活物

1.Objective To observe the expression of the co-expression plasmid of tissue-plasminogen activator (tPA) and vascular endothelia growth factor165 (VEGF165) in vascular smooth muscle cells (VSMC) and to study the effect of expressing products on the proliferation of VEC and VSMC and fibrinolysis activity.目的:观察组织纤溶酶原激活物(tPA)和血管内皮细胞生长因子165(VEGF165)基因共表达质粒在血管平滑肌细胞(VSMC)中的表达,并研究表达产物对血管内皮细胞(VEC)和VSMC增殖的影响和纤溶作用。

4)tissue type plasminogen activator组织纤溶酶原激活物

1.Objective To clonetissue type plasminogen activator (t PA) gene and to construct a new kind of recombinant vector containing human tissue type plasminogon activator (t PA) cNDA neither cytotoxiaty nor actovating prot oncogenes.目的利用基因工程技术克隆组织纤溶酶原激活物 (t PA)基因并构建一种无细胞毒性、不激活原癌基因的真核表达的pcDNA3。

5)tissue-type plasminogen activator组织型纤溶酶原激活物

1.Correlation between activity oftissue-type plasminogen activator and extracellular matrix in retina of rats during ischemia and reperfusion;缺血再灌注大鼠视网膜组织型纤溶酶原激活物活性与细胞外基质的相关性

2.Clinical significance and concentration changes of plasmatissue-type plasminogen activator and plasminogen activator inhibitor-1 antigen in patients with chronic heart failure;慢性心力衰竭患者血浆组织型纤溶酶原激活物和纤溶酶原激活物抑制物-1含量变化及其临床意义

3.DNA family shuffling oftissue-type plasminogen activator genes;组织型纤溶酶原激活物基因的DNA改组

6)tissue plasminogen activator组织型纤溶酶原激活物

1.Effect of benefiting Qi and promoting blood therapy(益气活血疗法) on the blood plasma levels oftissue plasminogen activator in a crowd of people with stroke at high risk;益气活血疗法对卒中高危人群血浆组织型纤溶酶原激活物释放的影响

2.Level oftissue plasminogen activator protein in pulmonary artery in acute pulmonary thromboembolism in rabbit;组织型纤溶酶原激活物在急性肺血栓栓塞肺动脉组织中的表达

3.Intravenous thrombolytic therapy with recombinant-tissue plasminogen activator for super early stage of cerebral infarction重组组织型纤溶酶原激活物rt-PA静脉溶栓治疗超早期脑梗死

延伸阅读

重组组织型纤溶酶原激活剂 ,栓体舒药物名称：重组组织型纤溶酶原激活剂英文名：Recombinant Human Tissue-type Plasiminogen别名：重组组织型纤溶酶原激活剂 ,栓体舒 外文名：Recombinant Human Tissue-type Plasiminogen, Actilyse, rTPA药理作用： 本药是一种糖蛋白，可激活纤溶酶原成为纤溶酶。当静脉使用时，本药在循环系统中只有与其纤维蛋白结合后才表现出活性，其纤维蛋白亲和性很高。当和纤维蛋白结合后，本品被激活，诱导纤溶酶原成为纤溶酶，溶解血块，但对整个凝血系统各组分的系统性作用是轻微的，因而不会出现出血倾向。本品不具抗原性，所以可重复使用。 适应症： 用于急性心肌梗塞的溶栓治疗；用于血流不稳定的急性大面积肺栓塞的溶栓疗法；用于急性缺血性脑卒中的溶栓治疗时，必须在脑梗塞症状发生的3小时内进行治疗，且需经影像检查（如CT扫描）除外颅内出血的可能。 用法用量： 除特别处方外，应在症状发生后尽快给药。心肌梗塞 对于发病后6小时内给予治疗的患者，应采取90分钟加速给药法mg静脉推注，其后30分钟内静脉滴注50mg剩余35mg在60分钟内静脉滴注，最大剂量达100mg。对于发病后6-12小时内给予治疗的患者，应采取3小时给药法。10mg静脉推注，其后1小时内脉滴注50mg，剩余40mg在2小时内静脉滴注，最大剂量达100mg。肺栓塞 应在2小时内给予100mg。最常用的给药方法为：10mg在1-2分钟内静脉推注，90mg在2小时内静脉滴注。缺血性脑卒中：推荐剂量为18mg/kg，量大剂量为90mg。先将剂量的10%静脉推入，剩余剂量在超过60分钟时间静脉滴注。 不良反应： 可能出现注射部位出血，如出现严重出血，则应停止溶栓疗法。 注意事项： 最近如有大血管穿刺，应考虑穿刺部位出血的危险。严重肝功能不良的病人，如凝血功能显著下降，则不应使用本药。对妊娠及哺乳的影响迄今尚无在妊娠及哺乳期使用本药的经验。对儿童的影响迄今尚无对儿童使用本药的经验。 注意事项：用药前给予口服抗凝剂会增加出血的危险。与其它纤溶药物合用时，请本酌情减量。 规格： 注射粉剂 20mg*1瓶，50mg*1瓶 类别：抗凝血药和溶血栓药